Evidence map›Paper›PMID 26997752›Full record

ArticleMRS bulletin2014

Materials that harness and modulate the immune system.

Jamal S Lewis, Krishnendu Roy, Benjamin G Keselowsky

Abstract read
In one paragraph

Article in MRS bulletin, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Quantum dot therapeutics: a new class of radical therapies.Journal of biological engineering · 2019
    Review
  13. Latent, Immunosuppressive Nature of Poly(lactic-ACS biomaterials science & engineering · 2018
    Article
  14. Article
  15. Article
  16. Review
  17. Micro and Nano Material Carriers for Immunomodulation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2016
    Review
  18. An introduction to biomaterial-based strategies for curbing autoimmunity.Experimental biology and medicine (Maywood, N.J.) · 2016
    Review
  19. Article
  20. Modulation of Immune Response Using Engineered Nanoparticle Surfaces.Small (Weinheim an der Bergstrasse, Germany) · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jamal S LewisUniversity of Florida, Gainesville.
Krishnendu RoyUniversity of Texas at Austin.
Benjamin G KeselowskyUniversity of Florida.

Funding

Dendritic Cell-Targeting Microparticles for Subcellularly-Targeted Delivery of InR01DK091658 · NIDDK · UNIVERSITY OF FLORIDA · PI KESELOWSKY, BENJAMIN GEORGE · 2012 to 2016
$1.6M
High-Throughput Evaluation of Dendritic Cell-Targeting Vaccine Particles for theR21AI094360 · NIAID · UNIVERSITY OF FLORIDA · PI KESELOWSKY, BENJAMIN GEORGE · 2012 to 2013
$388k
NIAID NIH HHS R21 AI094360NIDDK NIH HHS R01 DK091658
6 · The paper itself

Abstract

Recently, biomaterial scientists have married materials engineering and immunobiology to conceptualize new immunomodulatory materials. This special class of biomaterials can modulate and harness the innate properties of immune functionality for enhanced therapeutic efficacy. Generally, two fundamental strategies are followed in the design of immunomodulatory biomaterials: (1) immuno-evasive (immuno-mimetic, immuno-suppressing, or immuno-inert) biomaterials and (2) immuno-activating or immuno-enhancing biomaterials. This article highlights the development and application of a number of immunomodulatory materials, categorized by these two general approaches.

Identifiers

PMID26997752
PMCPMC4793183

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.